©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Induction of Oxidative Stress by Okadaic Acid Is Required for Activation of Transcription Factor NF-B (*)

(Received for publication, June 26, 1995; and in revised form, September 8, 1995)

Kerstin N. Schmidt E. Britta-Mareen Traenckner Beate Meier (1) Patrick A. Baeuerle (§)

From the Institute of Biochemistry, Albert-Ludwigs-University, Hermann-Herder-Str. 7, D-79104 Freiburg, Germany and the Tierärztliche Hochschule Hannover, Chemisches Institut, Bischofsholer Damm 15, D-30173 Hannover, Germany

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The widely used phosphatase 1 and 2A inhibitor okadaic acid is one of the many stimuli activating transcription factor NF-kappaB in cultured cells. Phosphorylation of IkappaB-alpha, one of NF-kappaB's inhibitory subunits, is a prerequisite for IkappaB degradation and the subsequent liberation of transcriptionally active NF-kappaB. This observation suggested that the phosphorylation status of IkappaB is influenced by an okadaic acid-sensitive phosphatase. In this study, we provide evidence that the effect of okadaic acid on NF-kappaB activation is indirect and dependent on the production of reactive oxygen intermediates rather than the inhibition of an IkappaB-alpha phosphatase. Okadaic acid was found to be a strong inducer of cellular H(2)O(2) and superoxide production in two distinct cell lines. The structurally unrelated phosphatase inhibitor calyculin A also induced oxidative stress. The delayed onset of reactive oxygen production in response to okadaic acid correlated with the delayed activation of NF-kappaB. Moreover, NF-kappaB induction was optimal at the same okadaic acid concentration that caused optimal H(2)O(2) production. Both reactive oxygen intermediates production and NF-kappaB activation were inhibited by the antioxidant pyrrolidine dithiocarbamate and 8-(diethylamino)octyl-3,4,5-trimethyoxybenzoate, a Ca chelator. Future experiments using phosphatase inhibitors in intact cells must consider that the compounds can act as strong inducers of oxidative stress, which provides one explanation for their tumor-promoting activity.


INTRODUCTION

A hallmark of the higher eukaryotic transcription factor NF-kappaB is its rapid post-translational activation by a plethora of distinct, mostly pathogenic stimuli, including viral and bacterial infections, inflammatory cytokines, UV and radiation, and oxidants (reviewed in Liou and Baltimore(1993), Baeuerle and Henkel(1994), and Siebenlist et al.(1994)). Many of these stimuli cause oxidative stress in cells, i.e. there is an increased production of ROIs, (^1)such as superoxide, hydrogen peroxide, hydroxyl radicals, and secondary reactive intermediates (reviewed in Schreck and Baeuerle(1991) and Schreck et al. (1992a)). Four lines of evidence suggest that ROIs, in particular H(2)O(2), serve as common second messenger-like molecules in the various pathways leading to NF-kappaB activation. First, many structurally unrelated antioxidants suppress NF-kappaB activation in response to most inducing conditions (reviewed in Schreck et al. (1992a) and Meyer et al. (1993a)). Dithiocarbamates (Schreck et al., 1992b), NAC (Staal et al., 1990; Schreck et al., 1991), and vitamin E derivatives (Suzuki et al., 1993) are particularly well studied in this respect. Second, in some cell lines NF-kappaB is directly activated upon addition of micromolar amounts of H(2)O(2) to the culture medium (Schreck et al., 1991; Meyer et al., 1993b). Third, stable overexpression of catalase impairs NF-kappaB activation while overexpression of Cu/Zn superoxide dismutase superinduces NF-kappaB activation in response to tumor necrosis factor alpha and OA (Schmidt et al., 1995). Last, re-exposure of hypoxic cells to dioxygen is a very potent NF-kappaB-inducing condition. (^2)In view of this requirement for ROIs we wondered whether there are inducers that bypass the ROI step and act more proximal on the NF-kappaBbulletIkappaB system. A recent study by Packer and colleagues (Suzuki et al., 1994) suggested that the phosphatase inhibitors OA and calyculin A are such ROI-independent inducers.

In unstimulated cells, NF-kappaB is known to reside in a latent form in the cytoplasm (Baeuerle and Baltimore, 1988a, 1988b). This form is stabilized by an inhibitory subunit, called IkappaB, which is tightly bound to a dimer frequently composed of the DNA-binding subunits p50 and p65 (RelA) (reviewed in Beg et al.(1993)). Upon cell stimulation, IkappaB is removed and the liberated NF-kappaB able to translocate into the nucleus and activate target genes by binding to regulatory elements in enhancers and promoters. The removal of IkappaB is controlled by protein phosphorylation. A yet unidentified kinase rapidly phosphorylates human IkappaB-alpha on serines 32 and 36 in response to various inducers (Brown et al., 1995; Traenckner et al., 1995). By phosphorylation, IkappaB-alpha which is still bound to NF-kappaB has apparently turned into a high affinity substrate for an ubiquitin-conjugating enzyme (Traenckner et al., 1994; Traenckner and Baeuerle, 1995). Following this phosphorylation-controlled ubiquitination, IkappaB-alpha is rapidly and completely degraded by the 20 S or 26 S proteasome (Palombella et al., 1994; Traenckner et al., 1994). Specific peptide inhibitors of the proteasome which stabilize the phosphoform of IkappaB have proven as potent inhibitors of NF-kappaB activation. Antioxidants also prevent the decay of IkappaB, however, by inhibition of the phosphorylation step and not the proteasome. Hence, antioxidants may act upstream of the kinase/phosphatase system, suggesting that the IkappaB phosphorylation is redox-controlled.

OA, a C fatty acid polyether compound, is a toxin which causes diarrhetic shellfish poisoning in humans (reviewed in MacKintosh and MacKintosh(1994) and Hardie et al. (1991)). It is produced by dinoflagellates and accumulates in the food chain in fish via sponges. OA and functionally related toxins, such as calyculin A, share two biological effects. First, they are very specific and potent inhibitors of protein phosphatases (PPs), which preferentially inhibit type 2A and 1 Ser/Thr-specific PPs. Second, OA and related toxins have nonphorbol tumor promoting activity, meaning they do not act by direct binding to PKC. In cell-free systems, nanomolar concentrations of OA can inhibit PPs whereas close to micromolar concentrations are required in intact cells (Hardie et al., 1991). This is because the concentration of PPs in the cytoplasm is in the micromolar range. The tumor promoting activity of OA and related toxins is not understood in detail.

OA has been reported to be a potent activator of NF-kappaB (Thévenin et al., 1990), supporting a role of protein phosphorylation in the process of NF-kappaB activation. One study provided evidence that OA and calyculin A activate NF-kappaB independently of ROIs (Suzuki et al., 1994), whereas another study suggested that the OA effect is sensitive toward antioxidants and that H(2)O(2) and L-buthionine-(S,R)-sulfoximine, a glutathione inhibitor, have a costimulatory effect on OA (Menon et al., 1993). Moreover, Menon et al.(1993) found that only tumor cells, but not primary cell lines, strongly respond to OA by the activation of NF-kappaB. In the present study, we have used a tumor cell line (HeLa) and a primary fibroblast line (F26) to address these contradictory results and investigate the possibility that OA relies on ROI production for NF-kappaB activation. We report that OA and calyculin A are very strong inducers of cellular H(2)O(2) and O(2) production in both a tumor and primary fibroblast line. This was optimal at approximately 0.9 µM OA, coinciding with the optimal induction of NF-kappaB. OA required a considerable lag time of 15-30 min to stimulate ROI production which again correlated with the delayed activation of NF-kappaB. The antioxidant PDTC prevented both the increased ROI production and NF-kappaB activation by OA but did not detectably influence the pattern of protein phosphorylation induced by the PP1/PP2A inhibitor in intact cells. We suggest that OA activates NF-kappaB indirectly via production of ROIs and that the tumor promoting activity of OA and functionally related compounds is due to a prooxidant activity, as suggested previously for phorbol esters (Cerutti, 1985).


MATERIALS AND METHODS

Cell Culture and Treatments

HeLa cells and F26 cells (a human primary fibroblast line) were grown in Dulbecco's modified essential medium supplemented with 10% fetal calf serum and 1% (w/v) penicillin/streptomycin (all purchased from GIBCO, Heidelberg, Federal Republic of Germany). For activation of NF-kappaB, cells were treated for the indicated periods of time with the indicated concentrations of the sodium salt of okadaic acid or calyculin A (Calbiochem) dissolved in ethanol. Respective solvent controls showed no effect of ethanol on NF-kappaB activation. The ammonium salt of PDTC (Sigma) was dissolved in distilled water and added at a final concentration of 100 µM to cells 1 h before addition of OA. TMB-8 (Calbiochem) was dissolved in ethanol and added 1 h before stimulation with OA.

Protein Phosphorylation

HeLa cells (1 times 10^6 per condition) were kept for 2 h in phosphate-free minimal essential medium (Sigma) in the presence of 10% dialyzed fetal calf serum. Thereafter, inorganic carrier-free [P]orthophosphate (Amersham) was added. After 3 h, two culture dishes received 100 µM PDTC. One hour later, one control and one PDTC-treated culture were stimulated with 0.4 µM OA for another hour. Cells were washed with ice-cold PBS and proteins extracted as described for EMSA. Equal amounts of protein were analyzed by reducing 10% SDS-PAGE.

FACS Analysis

HeLa cells (5 times 10^5 cells/5-cm dish) were left untreated or treated for with a respective amount of dimethylformamide, the solvent for DCFH, 150 µM PDTC, 0.7 µM OA, 150 µM H(2)O(2), or combinations of OA plus PDTC and H(2)O(2) plus PDTC. The pretreatment with PDTC was for 30 min. Treatment with OA was for 45 min and with H(2)O(2) for 20 min. Treated cells were washed with PBS, removed in PBS with a rubber policeman, and suspended in 0.5 ml of PBS of 37 °C. Fifty µM DCHF (Mobitech) dissolved in dimethylformamide were added and cells incubated for 15 min at 37 °C. Thereafter, cells were placed on ice and aliquots of 10,000 cells scanned in a Becton Dickinson FACSSORT according to Boissy et al.(1989) with excitation and emission settings of 495 and 525 nm, respectively. Histograms were analyzed with the software program Lysis II.

Determination of Cellular H(2)O(2)and OProduction

H(2)O(2) and O(2) released from approximately 2 times 10^5 HeLa or F26 cells grown in cuvettes was determined as described previously (McCord and Fridovich, 1969; Loschen et al., 1971; Meier et al., 1989, 1990; Schreck et al., 1992a).

Electrophoretic Mobility Shift Assay

Total cell extracts for EMSA were prepared by resuspending PBS-washed cell pellets in a high salt buffer containing the nonionic detergent Nonidet P-40 (Baeuerle and Baltimore, 1988b). After 10 min on ice, debris was removed by centrifugation for 10 min at 15,000 times g and the protein concentration in the remaining supernatant determined by a Coomassie Brilliant Blue assay (Bio-Rad). Equal amounts of protein (10-15 µg) were reacted with 10,000 cpm (Cerenkov counting) of a T4 polynucleotide kinase P-end-labeled double-stranded oligonucleotide with a high affinity NF-kappaB binding motif (Promega) under conditions described previously (Schreiber et al., 1989). For protein-DNA complex typing, 1 µl of p65-specific (Santa Cruz Biotechnology) and IkappaB-alpha-specific rabbit antisera (Zabel et al., 1993) were directly added to the DNA binding reaction. DNA binding reactions were analyzed by electrophoresis on native 4% polyacrylamide gels. Dried gels were exposed to Kodak XR5 films. P radioactivity in NF-kappaBbulletDNA complexes was quantitated by a beta imaging system (Molecular Dynamics).


RESULTS

OA Activates a Prototypic NF-kappaB Complex by IkappaB-alpha Degradation

In HeLa cells, 0.7 µM OA strongly induced an activity which retarded upon native gel electrophoresis a P-labeled oligonucleotide with a consensus NF-kappaB binding site (Fig. 1A, compare lanes 1 and 2). Formation of the newly induced protein-DNA complex was completely prevented in the presence of an antibody specific for the transactivating p65 NF-kappaB subunit (lane 6, compare to lane 1), while a control antibody against the inhibitory subunit IkappaB-alpha was ineffective (lane 4). This shows that okadaic acid induces a prototypic NF-kappaB complex containing the transactivating p65 (RelA) subunit. The activation of NF-kappaB by OA involved the proteolytic degradation of the inhibitory subunit IkappaB-alpha, as shown by Western blotting with an IkappaB-alpha-specific polyclonal antibody (Fig. 1B). Hence, the effects of OA on the NF-kappaB/IkappaB system were not distinguishable from those of other inducers of the transcription factor.


Figure 1: The effect of OA on NF-kappaB activation and IkappaB-alpha stability in intact cells. HeLa cells were treated for 1 h with the indicated concentrations of OA. A, activation of NF-kappaB DNA binding activity by OA. Total cell extracts were prepared from control (lanes 1, 3, and 5) and OA-treated cells (lanes 2, 4, and 6) and analyzed by EMSA using a P-labeled oligonucleotide probe containing a high-affinity kappaB motif. Cell extracts were incubated with a control antibody directed against human IkappaB-alpha (lanes 3 and 4) or an antibody against the p65 NF-kappaB subunit (lanes 5 and 6). An OA-inducible protein-DNA complex which is abbrogated by anti-p65 but not by anti-IkappaB-alpha is indicated by a filled arrowhead. A faster-migrating nonspecific complex was unaffected. A small filled arrowhead indicates the position of an immune complex. The open arrowhead marks the position of the unbound DNA probe. A fluorogram of a native gel is shown. B, OA causes a degradation of IkappaB-alpha. Total cell extracts of control (lane 1) and OA-treated HeLa cells (lane 2) were subjected to reducing SDS-PAGE and proteins transferred on filters for Western blotting. IkappaB-alpha was visualized by an affinity-purified polyclonal antibody against recombinant human IkappaB-alpha and enhanced chemiluminescent staining as described (Henkel et al., 1993). A fluorogram of a section of the filter is shown. An arrowhead indicates the position of a 38-kDa IkappaB-alpha-specific signal.



An Antioxidant Prevents NF-kappaB Activation by OA But Not OA-induced Protein Phosphorylation

The effect of many stimuli activating NF-kappaB is suppressed by pretreatment of cells with antioxidants (reviewed in Schreck et al. (1992a)). Vitamin E and derivatives, various thiol reagents, metal chelators, and phenolic scavengers have been reported to prevent NF-kappaB activation. Particularly potent are dithiocarbamates (Schreck et al., 1992b). As shown in Fig. 2A, the induction of NF-kappaB in HeLa cells by 0.7 µM OA was completely suppressed when cells were preincubated for 1 h with 100 µM of the antioxidant PDTC. In contrast to a previous report (Suzuki et al., 1994), we observed also that 30 mM NAC prevented OA-induced NF-kappaB activation (data not shown). This suggested that OA relied on the induction of oxidative stress for the activation of NF-kappaB. To investigate whether PDTC still allowed for an increased incorporation of phosphate into polypeptides in response to OA, cell cultures were incubated with inorganic [P]phosphate and proteins analyzed by reducing SDS-PAGE and fluorography. Under control conditions, treatment with 0.4 µM OA caused an increased incorporation of radioactive phosphate, which was most pronounced with proteins of apparent molecular masses between 40 and 97 kDa (Fig. 2B, compare lanes 1 and 2). In the presence of 100 µM PDTC, OA still induced an increased protein phosphorylation and the pattern of phosphoproteins was not detectably changed (lanes 3 and 4; compare lanes 2 and 4). This indicates that PDTC in intact cells did not act by neutralizing the phosphatase inhibitory activity of OA nor by inhibiting major protein kinases responding to OA. In the following we tested the idea that OA is an inducer of oxidative stress.


Figure 2: The effect of the antioxidant PDTC on the activation of NF-kappaB by OA. A, PDTC prevents NF-kappaB activation by OA. HeLa cells were pretreated for 1 h with PDTC (lanes 3 and 4) followed by addition of the indicated amount of OA (lanes 2 and 3). Total cell extracts were analyzed by EMSA for the DNA binding activity of NF-kappaB. For illustration, see legend to Fig. 1. B, PDTC does not detectably interfere with OA-induced protein phosphorylation. HeLa cells were grown in phosphate-free medium followed by the addition of carrier-free inorganic [P]phosphate. Control HeLa cells (lanes 1 and 2) or cells preincubated with 100 µM PDTC (lanes 3 and 4) were treated with the indicated concentration of OA (lanes 2 and 4). Total cell extracts were analyzed by reducing 10% SDS-PAGE. An autoradiogram is shown. The molecular mass standards in kDa are indicated on the left (200, myosin heavy chain; 97, phosphorylase b; 67, bovine serum albumin; 46, ovalbumin; 30, carbonic anhydrase; 21, trypsin inhibitor; 14, lysozyme).



OA Increases Cellular ROI Production which Is Prevented by PDTC

DCFH is a dye that allows to monitor cellular ROI production by FACS analysis (Boissy et al., 1989). As shown in Fig. 3A, treatment of HeLa cells for 20 min with 150 µM H(2)O(2) caused a 3.5-fold increased oxidation of intracellular DCFH. If cells were pretreated with 150 µM PDTC the oxidation of DCFH was effectively prevented. In this experiment, PDTC also strongly reduced the basal peroxide production of HeLa cells. Dimethylformamide, the solvent for DCFH, had no effect (data not shown). Treatment of cells with 0.7 µM OA also increased DCFH oxidation by 2-2.5-fold (Fig. 3B). Again, PDTC significantly quenched the oxidation of DCFH caused by OA. These data show that OA induces an increased cellular production of ROIs, including peroxides, which is prevented by the antioxidant PDTC. In the following, we tried to identify the ROI species produced in response to OA.


Figure 3: The effect of PDTC on OA-stimulated cellular peroxide production. HeLa cells were treated as described under ``Materials and Methods'' with the indicated compounds. Thereafter, cells were resuspended in PBS, incubated with DCFH, and analyzed by FACS. A, the effect of H(2)O(2) and PDTC on the oxidation state of cellular DCFH. Results from one representative experiment are shown. B, the effect of OA and PDTC on the oxidation state of cellular DCFH. Results from three independent experiments are shown. The bar reflects the standard deviation from the mean.



OA Strongly Induces H(2)O(2)and O Production in HeLa and F26 Cells

HeLa cells and F26, a human fibroblast primary cell line, were tested for the production of H(2)O(2) and O(2) in response to various concentrations of OA. Cells were grown on the inner surface of cuvettes. The amount of H(2)O(2) released into the culture medium was determined fluorometrically by oxidation of scopoletin (Loschen et al., 1971) and that of O(2) photometrically by reduction of cytochrome c (McCord and Fridovich, 1969). In both cell lines, OA triggered a strong and dose-dependent production of H(2)O(2) (Fig. 4, A and B). An almost identical dose-response curve was seen for the production of O(2) (data not shown). Maximal production of ROIs was reached at a concentration of 0.9 µM OA. At higher OA concentrations, ROI production declined and increasing desintegration of cells was observed microscopically. HeLa and F26 cells showed cell type-specific differences with respect to the OA dose dependence of ROI production but had the same maximum. These data provide direct evidence that the phosphatase inhibitor OA induces oxidative stress in two distinct cell types. The structurally unrelated phosphatase inhibitor calyculin A, which also activates NF-kappaB (Suzuki et al., 1994), induced equally high levels of H(2)O(2) and O(2) production in HeLa cells as OA but at a higher concentration (Fig. 4C). Maximal induction of oxidative stress was observed at 30 µM calyculin and declined with higher concentrations of the compound.


Figure 4: The effect of phosphatase inhibitors on the cellular production of ROIs. A, OA-induced H(2)O(2) production in HeLa cells. B, OA-induced H(2)O(2) production in F26 cells. H(2)O(2) released from HeLa and F26 cells at the indicated concentrations of OA was determined as described (Loschen et al., 1971). Approximately five times higher rates were determined for superoxide release with an identical dose-response behavior. C, calyculin A-induced H(2)O(2) and O(2) production in HeLa cells. HeLa cells were treated with the indicated concentrations of calyculin A and the release of H(2)O(2) (right) determined. The relation to the release of O(2) (not shwon) is indicated on the left. Several independent experiments were performed from which typical results are shown.



H(2)O(2)Production and NF-kappaB Activation Show an Overlapping OA Dose-Response

We investigated whether the production of ROIs was related to the activation of transcription factor NF-kappaB in a dose-response to OA. In HeLa cells, weak activation of NF-kappaB was observed after treatment of cells with 0.1 µM OA (Fig. 5A, lane 2). The activation increased weakly up to 0.6 µM OA. Optimal activation occurred between 0.7 and 1 µM OA, as shown quantitated in Fig. 4B. The OA dose for optimal NF-kappaB activation was the same as that for optimal H(2)O(2) production in HeLa cells (compare Fig. 5B and Fig. 3A). At higher OA concentrations, NF-kappaB activation declined, as was seen with the H(2)O(2) production. In F26 cells, a similar correlation between H(2)O(2) production and NF-kappaB activation in response to OA treatment was observed (Fig. 6, A and B). A strong NF-kappaB activation was seen at OA concentrations >0.4 µM (Fig. 6A, lane 5), which again corresponded to the OA concentrations that yielded an increased production of H(2)O(2) (see Fig. 4B). These data support a causal relationship between the extent of ROI production and NF-kappaB activation in response to OA treatment of HeLa and F26 cells.


Figure 5: Dose dependence of NF-kappaB activation by OA in HeLa tumor cells. A, EMSA analysis. HeLa cell cultures were treated with the indicated concentrations of OA and cell extracts analyzed for kappaB-specific DNA binding activity using EMSA. For details see legend to Fig. 1. A section of a fluorogram from a native gel is shown. A filled arrowhead indicates the position of the OA-induced NF-kappaBbulletDNA complex. A faster-migrating nonspecific complex was unaffected. B, quantitation of NF-kappaB activity. The P radioactivity in the NF-kappaBbulletDNA complexes was quantitated by a beta imager and is shown plotted against the OA concentration. The maximal NF-kappaB activation seen at 0.9 µM OA was set to 100%.




Figure 6: Dose dependence of NF-kappaB activation by OA in F26 primary fibroblasts. A, EMSA analysis. F26 cell cultures were treated with the indicated concentrations of OA and cell extracts analyzed for kappaB-specific DNA binding activity using EMSA. For details, see the legend to Fig. 1. A section of a fluorogram from a native gel is shown. A filled arrowhead indicates the position of the OA-induced NF-kappaBbulletDNA complex. A faster-migrating nonspecific complex was unaffected. B, quantitation of NF-kappaB activity. The P radioactivity in the NF-kappaBbulletDNA complexes was quantitated by a beta imager and is shown plotted against the OA concentration. The maximal NF-kappaB activation seen at 1 µM OA was set to 100%.



Temporal Coincidence of H(2)O(2)Production and NF-kappaB Activation by OA

A second criterion for a causal relationship between NF-kappaB activation and H(2)O(2) production in response to OA is a kinetic coincidence of the two events. HeLa cells showed an approximately 15-min delay before 0.7 µM OA could induce H(2)O(2) production (Fig. 7A). After 40-50 min, H(2)O(2) production started to plateau. The activation of NF-kappaB showed a very similar kinetic profile (Fig. 7B). There was no significant activation of NF-kappaB before a 20-min OA treatment and a plateau was reached after 60 min. F26 cells required approximately 30 min before there was a significant increase in H(2)O(2) production (Fig. 8A). In this cell line, NF-kappaB activity did not strongly increase before 40 min after addition of 0.7 µM OA (Fig. 8B). These data show that NF-kappaB activation follows the production of H(2)O(2) in OA-treated cells which is consistent with the idea that H(2)O(2) serves as a messenger of NF-kappaB activation (Schmidt et al., 1995).


Figure 7: Time dependence of H(2)O(2) production and NF-kappaB activation in response to OA in HeLa tumor cells. A, H(2)O(2) production. The H(2)O(2) released by HeLa cells in response to a treatment with 0.7 µM OA was determined and is shown plotted against time. B, NF-kappaB activity. Total cell extracts from HeLa cells treated for the indicated periods of time with 0.7 µM OA were prepared and analyzed by EMSA as described in the legend to Fig. 1. A section of a fluorogram is shown. A filled arrowhead indicates the position of the OA-inducible NF-kappaBbulletDNA complex.




Figure 8: Time dependence of H(2)O(2) production and NF-kappaB activation in response to OA in F26 fibroblasts. A, H(2)O(2) production. The H(2)O(2) released by F26 cells in response to a treatment with 0.7 µM OA was determined and is shown plotted against time. B, NF-kappaB activity. Total cell extracts from F26 cells treated for the indicated periods of time with 0.7 µM OA were prepared and analyzed by EMSA as described in the legend to Fig. 1. A section of a fluorogram is shown. A filled arrowhead indicates the position of the OA-inducible NF-kappaBbulletDNA complex.



A Calcium Chelator Prevents Both H(2)O(2)Production and NF-kappaB Activation by OA in a Similar Concentration Range

A third criterion for a causal relationship between NF-kappaB activation and H(2)O(2) production in response to OA is that both events are inhibited by a drug within a similar concentration range. Here, we tested TMB-8, a chelator of intracellularly released calcium. TMB-8 prevented the production of H(2)O(2) in HeLa cells treated with 0.7 µM OA in a dose-dependent manner (Fig. 9A), suggesting that intracellularly released Ca was a cofactor in the induction of oxidative stress. Half-maximal inhibition was obtained with 300 µM of the compound. TMB-8 had a similar effect on NF-kappaB activation (Fig. 9B). Two hundred µM TMB-8 were sufficient to completely suppress NF-kappaB activation in response to 0.7 µM OA. This corresponded to a 30% inhibition of H(2)O(2) production. The nonlinear dose-response behavior of NF-kappaB activation (see Fig. 4A and Fig. 5) makes it likely that such a reduction of H(2)O(2) production is sufficient to prevent NF-kappaB activation.


Figure 9: The effect of TMB-8 on the production of H(2)O(2) and the activation of NF-kappaB in response to OA. HeLa cells were pretreated for 1 h with the indicated concentrations of TMB-8 followed by stimulation with 0.4 µM OA. A, H(2)O(2) release. H(2)O(2) production in response to 0.4 µM OA is shown as % of maximal production in the absence of TMB-8. B, NF-kappaB activity. Total cell extracts from HeLa cells were analyzed for kappaB-specific DNA binding activity by EMSA as described in the legend to Fig. 1. A section of a fluorogram from a native gel is shown. The filled arrowhead indicates the position of the OA-induced NF-kappaBbulletDNA complex, the open arrowhead indicates the position of nonspecific complexes.




DISCUSSION

The mechanism by which the PP inhibitor OA activates NF-kappaB is a matter of debate. Packer and colleagues (Suzuki et al., 1994) reported that the activation of NF-kappaB by OA or calyculin A cannot be prevented by the antioxidants NAC (20 mM) or dihydrolipoate (1 mM), suggesting that OA does not require a ROI step for signaling. However, the antioxidant rotenone (5 µM), which inhibits tumor necrosis factor alpha signaling (Schulze-Osthoff et al., 1993), prevented OA-induced NF-kappaB activation. It was speculated that the inhibitory effect of rotenone on OA was not caused by its antioxidative potential but the reduction of cellular ATP levels by approximately 50% (Suzuki et al., 1994). However, it is questionable whether this degree of ATP depletion was sufficient to inhibit protein kinases in the cell, most of which have K(m) values for ATP in the micromolar range. Here we show that the antioxidant PDTC is a potent inhibitor of OA activity and ROI production without having an apparent influence on overall protein phosphorylation. PDTC was also shown to prevent H(2)O(2) production and NF-kappaB activation in response to Fc2a receptor stimulation in J774 cells (Muroi et al., 1994). It seems that antioxidants profoundly differ with respect to their effect on OA-induced NF-kappaB activation. These differences may come from a distinct uptake, subcellular distribution, or metabolism of the antioxidants in the cell. Non-thiol antioxidants, such as PDTC and rotenone, are presumably less rapidly metabolized or taken up better than the more physiological compounds NAC and lipoic acid. Menon et al.(1993) have observed that 30 mML-cysteine prevents both OA- and tumor necrosis factor alpha-induced NF-kappaB activation in primary and transformed MRC-5 cells. It was also observed by these authors that the NF-kappaB activation by OA was enhanced in the presence of either micromolar concentrations of H(2)O(2) or 5 mM of the glutathione synthesis inhibitor L-buthionine-(S,R)-sulfoximine in several cell lines. We have observed that 30 mM NAC suppresses NF-kappaB inhibition in HeLa cells (data not shown). These data would also be consistent with a requirement of a pro-oxidant condition for OA signaling.

All published studies relied on a pharmacological approach to test for an involvement of ROIs in the signaling of OA. The conflicting results prompted us to directly investigate whether OA leads to an enhanced cellular production of ROIs. We found that OA is a strong inducer of cellular ROI production by two distinct approaches. First, OA was shown to increase the cellular oxidation of the dye DCFH; second, an increased H(2)O(2) and O(2) production was directly measured in culture supernatants of OA-stimulated HeLa tumor cells and F26 primary fibroblasts. ROI production and the activation of NF-kappaB correlated both with respect to kinetics and dose dependence. We could not observe that only the tumor cell line would respond to OA treatment; F26 primary fibroblasts showed a similar responsiveness as HeLa tumor cells. NF-kappaB activation by OA was also reported in human B lymphocytes, another type of primary cells (Rieckmann et al., 1992). Hence, the finding that primary cells are less or unresponsive toward OA cannot be generalized.

The slow kinetic of ROI production in response to OA suggests that a number of reactions have to occur before NF-kappaB is activated. Alternatively, it may reflect a very slow uptake of the PP inhibitor into the cell. Inhibition of PP1 and PP2A may allow enhanced phosphorylation of a substrate X. Phosphorylated X may then, for instance, cause directly or indirectly a rise in intracellular calcium which is where TMB-8 might interfere in the signaling pathway. Intracellular calcium is also required for activation of NF-kappaB by endoplasmic reticulum stress-inducing conditions and two drugs inhibiting the Ca-ATPase in the endoplasmic reticulum membrane turned out to be potent NF-kappaB inducers (Pahl and Baeuerle, 1995). (^3)There is one report that calyculin A induces an increase in intracellular calcium (Ishihara et al., 1989). Whether PKC is activated and required in a subsequent step needs future studies. Thévenin et al.(1989) provided evidence that PKC is not involved in OA signaling. Very clearly, ROIs are produced in response to OA stimulation of cells. It is likely that the ROI scavenger PDTC as well as the costimuli H(2)O(2) and L-buthionine-(S,R)-sulfoximine act at this late stage of OA signaling. This is also where signals from other NF-kappaB inducers, such as tumor necrosis factor alpha, interleukin-1, and UV light may converge into the pathway. As described in the Introduction, an as yet unidentified kinase/phosphatase system appears to be controlled by ROIs and ultimately activates NF-kappaB through a phosphorylation-controlled proteolytic degradation of IkappaB-alpha. The very slow action of OA and the apparent involvement of ROIs make it very unlikely that an IkappaB-alpha phosphatase is a direct target for OA inhibition. In conclusion, this study cannot support the previous notion that OA activates NF-kappaB independently of ROIs. On the contrary, OA was found to be a strong inducer of oxidative stress which may provide a further explanation for its broad biological effects.

Our observation that both OA and calyculin A are potent inducers of oxidative stress may well explain their tumor promoting potential. Tumor promotion by OA inhibitors could not be correlated to events controlling the cell cycle. On the contrary, in myeloid leukemic cells OA induced cell cycle arrest and apoptosis (Ishida et al., 1992) and in raf and ret-II-transformed fibroblasts the drug reversed the transformed phenotype to that of normal contact inhibited cells (Sakai et al., 1989; reviewed in MacKintosh and MacKintosh (1994)). Based on our present finding that both OA and calyculin A potently induce oxidative stress we would like to propose that PP1 and PP2A inhibition has a tumor promoting effect by virtue of deregulating a phosphorylation-controlled ROI-producing cellular process. A similar mechanism was proposed for the tumor-promoting activity of phorbol esters (Cerutti, 1985), which are activators of several PKC isozymes. A number of observations are consistent with this hypothesis. OA has been reported to cause mutagenesis of eukaryotic but not prokaryotic DNA (Aonuma et al., 1991). DNA damage is a well documented effect of oxidative stress (reviewed in Halliwell and Gutteridge (1989)). Upon long-term treatment, OA can cause programmed cell death (Ishida et al., 1992), a phenomena known to be associated with oxidative stress (reviewed in Buttke and Sandström(1994)). Although OA and calyculin A are tumor promoters which unlike PKC do not directly bind phorbol esters, they nevertheless cause an activation of the kinase in NRK cells (Gopalakrishna et al., 1992). Intriguingly, the induction of PKC by OA and calyculin A showed a lag phase of 15-30 min, as was observed in our study for the production of ROIs and the activation of NF-kappaB. This raises the possibility that PKC is involved in tumor promotion, ROI production, and NF-kappaB activation by the non-phorbol tumor promoter OA. An involvement of PKC would also be consistent with the inhibitory effect of the Ca chelator TMB-8. Ca is required for activation of PKC and TMB-8 has been shown to inhibit PKC activation (Christiansen et al., 1986).


FOOTNOTES

*
This work was supported by the Deutsche Forschungsgemeinschaft (Ba957/1-3) and the European Community Biotechnology Programme, and is a partial fulfilment of the doctoral thesis (for K. N. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 49-761-203-5222; Fax: 49-761-203-5257.

(^1)
The abbreviations used are: ROIs, reactive oxygen intermediates; DCFH, 2`,7`-dichlorofluoresceine diacetate; EMSA, electrophoretic mobility shift assay; FACS, fluorescence-activated cell sorting; NAC, N-acetyl-L-cysteine; OA, okadaic acid; PDTC, pyrrolidinedithiocarbamate; PBS, phosphate-buffered saline; PP, protein phosphatase; PKC, protein kinase C; PAGE, polyacrylamide gel electrophoresis; TMB-8, 8-(diethylamino)octyl-3,4,5-trimethoxybenzoate.

(^2)
R. Rupec and P. Baeuerle,(1995) Eur. J. Biochem., in press.

(^3)
H. L. Pahl and P. A. Baeuerle, manuscript submitted.


ACKNOWLEDGEMENTS

We are extremely grateful to Dr. Ralf Hess for help with the FACS analysis, J. M. Müller for many helpful suggestions and valuable advice, and Dr. Heike L. Pahl for carefully reading the manuscript.


REFERENCES

  1. Aonuma, S., et al. (1991) Mutation Res. 250, 375-381 [Medline] [Order article via Infotrieve]
  2. Baeuerle, P. A., and Baltimore, D. (1988a) Cell 53, 211-217 [Medline] [Order article via Infotrieve]
  3. Baeuerle, P. A., and Baltimore, D. (1988b) Science 242, 540-546 [Medline] [Order article via Infotrieve]
  4. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179 [CrossRef][Medline] [Order article via Infotrieve]
  5. Beg, A. A., Finco, G., Nantermet, P. V., and Baldwin, A. S. (1993) Mol. Cell. Biol. 13, 3301-3310 [Abstract]
  6. Boissy, R. E., Trinkle, L. S., and Nordlund, J. J. (1989) Cytometry 10, 779-787 [Medline] [Order article via Infotrieve]
  7. Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995) Science 267, 1485-1488 [Medline] [Order article via Infotrieve]
  8. Buttke, T. M., and Sandström, P. A. (1994) Immunol. Today 15, 7-10 [CrossRef][Medline] [Order article via Infotrieve]
  9. Cerutti, P. (1985) Science 227, 375-381 [Medline] [Order article via Infotrieve]
  10. Christiansen, N. O., Larsen, C. S., and Juhl, H. (1986) Biochim. Biophys. Acta 882, 57-62 [Medline] [Order article via Infotrieve]
  11. Gopalakrishna, R., Chen, Z. H., and Gundimeda, U. (1992) Biochem. Biophys. Res. Commun. 189, 950-957 [Medline] [Order article via Infotrieve]
  12. Halliwell, B., and Gutteridge, J. M. C. (1989) Free Radicals in Biology and Medicine, 2nd Ed., Clarendon Press, Oxford
  13. Hardie, D. G., Haystead, T. A. J., and Sim, A. T. R. (1991) Methods Enzymol. 201, 469-476 [Medline] [Order article via Infotrieve]
  14. Henkel, T., Machleidt, T., Alkalay, I., Krönke, M., Ben-Neriah, Y., and Baeuerle, P. A. (1993) Nature 365, 182-185 [CrossRef][Medline] [Order article via Infotrieve]
  15. Ishida, Y., Furukawa, Y., Decprio, J. A., Masaki, S., and Griffin, J. D. (1992) J. Cell. Physiol. 150, 484-492 [Medline] [Order article via Infotrieve]
  16. Ishihara, H., Ozaki, H., Sato, K., Hori, M., Karaki, H., Watabe, S., Kato, Y., Fusetani, N., Hashimoto, K., Uemura, D., et al. (1989) J. Pharmacol. Exp. Ther. 250, 388-396 [Abstract]
  17. Liou, H. C., and Baltimore, D. (1993) Curr. Opin. Cell Biol. 5, 477-487 [Medline] [Order article via Infotrieve]
  18. Loschen, G., Flohé, L., and Chance, B. (1971) FEBS Lett. 18, 261-264 [CrossRef][Medline] [Order article via Infotrieve]
  19. MacKintosh, C., and MacKintosh, R. W. (1994) Trends Biochem. Sci. 19, 444-448 [CrossRef][Medline] [Order article via Infotrieve]
  20. McCord, J. M., and Fridovich, I. (1969) J. Biol. Chem. 244, 6049-6055 [Abstract/Free Full Text]
  21. Meier, B., Radeke, H. H., Selle, S., Younes, M., Sies, H., Resch, K., and Habermehl, G. G. (1989) Biochem. J. 263, 539-545 [Medline] [Order article via Infotrieve]
  22. Meier, B., Radeke, H. H., Selle, S., Habermehl, G. G., Resch, K., and Sies, H. (1990) Biol. Chem. Hoppe-Seyler 371, 1021-1025 [Medline] [Order article via Infotrieve]
  23. Menon, S. D., Qin, S., Guy, G. R., and Tan, Y. H. (1993) J. Biol. Chem. 268, 26805-26812 [Abstract/Free Full Text]
  24. Meyer, M., Schreck, R., M ü ller, J. M., and Baeuerle, P. A. (1993a) in Oxidative Stress on Cell Activation and Viral Infection (Pasquier, C., et al. , ed) pp. 217-235, Birkh ä user Verlag AG, Basel
  25. Meyer, M., Schreck, R., and Baeuerle, P. A. (1993b) EMBO J. 12, 2005-2015 [Abstract]
  26. Meyer, R., Lahm, H.-W., Schläger, E. J., van Loon, A. P. G. M., and Scheidereit, C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 966-970 [Abstract]
  27. Muroi, M., Muroi, Y., and Suzuki, T. (1994) J. Biol. Chem. 269, 30561-30568 [Abstract/Free Full Text]
  28. Pahl, H. L., and Baeuerle, P. A. (1995) EMBO J. 14, 2580-2588 [Abstract]
  29. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785 [Medline] [Order article via Infotrieve]
  30. Rieckmann, P., Thévenin, C., and Kehrl, J. H. (1992) Biochem. Biophys. Res. Commun. 187, 51-57 [Medline] [Order article via Infotrieve]
  31. Sakai, R., Ikeda, I., Kitani, H., Fujiki, H., Takaku, F., Rapp, U., Sugimura, T., and Nagao, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9945-9950
  32. Schmidt, K. N., Amstad, P., Cerutti, P., and Baeuerle, P. A. (1995) Chem. Biol. 2, 13-22 [Medline] [Order article via Infotrieve]
  33. Schreck, R., and Baeuerle, P. A. (1991) Trends Cell Biol. 1, 39-42 [CrossRef]
  34. Schreck, R., Rieber, P., and Baeuerle, P. A. (1991) EMBO J. 10, 2247-2258 [Abstract]
  35. Schreck, R., Albermann, K., and Baeuerle, P. A. (1992a) Free Rad. Res. Comms. 17, 221-237 [Medline] [Order article via Infotrieve]
  36. Schreck, R., Meyer, B., Männel, D., Dröge, W., and Baeuerle, P. A. (1992b) J. Exp. Med. 175, 1181-1194 [Abstract]
  37. Schreiber, E., Matthias, P., Müller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419 [Medline] [Order article via Infotrieve]
  38. Schulze-Osthoff, K., Beyaert, R., Vandevoorde, V., Haegeman, G., and Fiers, W. (1993) EMBO J. 12, 3095-3104 [Abstract]
  39. Siebenlist, U., Franzoso, G., and Brown, K. (1994) Annu. Rev. Cell Biol. 10, 405-455 [CrossRef]
  40. Staal, F. J. T., Roederer, M., and Herzenberg, L. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9943-9947 [Abstract]
  41. Suzuki, Y. J., Tsuchiya, M., and Packer, L. (1993) Free Rad. Res. Comms. 18, 115-122 [Medline] [Order article via Infotrieve]
  42. Suzuki, Y. J., Mizuno, M., and Packer, L. (1994) J. Immunol. 153, 5008-5015 [Abstract/Free Full Text]
  43. Thévenin, C., Kim, S.-J., Rieckmann, P., Fujiki, H., Norcross, M. A., Sporn, M. B., Fauci, A. S., and Kehrl, J. H. (1990) New Biol. 2, 793-800 [Medline] [Order article via Infotrieve]
  44. Traenckner, B. M., and Baeuerle, P. A. (1995) J. Cell Sci., in press
  45. Traenckner, B. M., Wilk, W., and Baeuerle, P. A. (1994) EMBO J. 13, 5433-5441 [Abstract]
  46. Traenckner, B. M., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., and Baeuerle, P. A. (1995) EMBO J. 14, 2876-2883 [Abstract]
  47. Zabel, U., Henkel, T., dos Santos Silva, M. A., and Baeuerle, P. A. (1993) EMBO J. 12, 201-211 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.